
At its November 2026 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended seven new medicines for European Union marketing authorization and endorsed a quarterly HIV prevention ring under EU-Medicines for all. The positive opinions span oncology, resistant hypertension, and diabetes, setting important regulatory precedents for clinical trial sponsors, academic medical centers, and international research collaborations.
What happened at the November 2026 meeting
The European Medicines Agency (EMA) concluded the monthly plenary of its Committee for Medicinal Products for Human Use (CHMP), held from 9 to 12 November 2026, recommending seven new medicines for European Union marketing authorization. Meeting highlights published on 13 November 2026 confirmed positive opinions for three new active substances, two biosimilar insulins, and two generic formulations, bringing the committee’s 2026 total of recommended new medicines to 79.
In parallel, the CHMP adopted a positive scientific opinion under the EU-Medicines for all (EU-M4All) procedure for a higher-strength, three-month dapivirine vaginal ring for HIV prevention outside the EU. The committee also endorsed 11 extensions of therapeutic indication, raising 2026 label expansions to 108. Major extensions included Gazyvaro (obinutuzumab) for moderate-to-severe active systemic lupus erythematosus and Isturisa (osilodrostat) for pediatric Cushing’s syndrome. The committee confirmed refusals for KemSu and Meplyffa upon re-examination and recorded the withdrawal of applications for Amlypave and Qezzaqar.
Key details of recommended medicines
The newly recommended products broaden therapeutic options across oncology, cardiovascular medicine, endocrinology, and hematology while introducing biosimilar and generic competition.
| Medicine | Active Substance (INN) | Category | Applicant | Therapeutic Indication |
|---|---|---|---|---|
| Aumseqa | aumolertinib | New active substance | SFL Pharmaceuticals Deutschland GmbH | Non-small cell lung cancer (NSCLC) in adults |
| Baxfendy | baxdrostat | New active substance | AstraZeneca AB | Arterial hypertension in adults insufficiently controlled on 2+ medicines |
| Zybrivo | sintilimab | New active substance | Fortvita Biologics (Ireland) Limited | First-line non-squamous NSCLC in adults (with pemetrexed/platinum) |
| Garzulys | insulin aspart | Biosimilar | Sciencepharma Sp. z o.o. | Diabetes mellitus in adults, adolescents, and children aged 1+ |
| Donrafylix | insulin aspart | Biosimilar | Kuraci | Diabetes mellitus in adults, adolescents, and children aged 1+ |
| Fondaparinux sodium Evumed | fondaparinux sodium | Generic | Evumed Limited | Venous thromboembolism prevention, DVT, pulmonary embolism, and ACS |
| Ruxolitinib Krka | ruxolitinib | Generic | KRKA tovarna zdravil d.d. Novo mesto | Myelofibrosis, polycythaemia vera, and graft-versus-host disease |
| Dapivirine Vaginal Ring (100 mg) | dapivirine | EU-M4All opinion | Population Council | HIV-1 prevention in women aged 16+ in non-EU settings |
Baxfendy (baxdrostat) is a first-in-class selective aldosterone synthase inhibitor targeting CYP11B2 without blocking cortisol synthesis, offering a new pathway for resistant hypertension. Aumseqa (aumolertinib) is a third-generation irreversible EGFR-TKI targeting sensitizing and T790M resistance mutations in NSCLC. Zybrivo (sintilimab) is a PD-1 inhibitor recommended in combination with chemotherapy for advanced non-squamous NSCLC lacking EGFR or ALK aberrations.
Garzulys and Donrafylix expand biosimilar insulin aspart choices, matching reference product Novorapid in efficacy and safety. In generics, Fondaparinux sodium Evumed provides an anticoagulant pentasaccharide, while Ruxolitinib Krka offers an accessible generic JAK1/JAK2 inhibitor. The EU-M4All opinion endorses a 100 mg silicone ring providing sustained dapivirine release over three months, reducing replacements from monthly to quarterly for women and adolescent girls aged 16 and older.
Background and regulatory context
The November opinions illustrate significant regulatory contrasts between European and US regulators. Sintilimab received a Complete Response Letter from the US FDA in 2022 after its advisory committee questioned relying exclusively on China-based data from the Phase III ORIENT-11 trial (NCT03607539). In contrast, the CHMP determined that the biological mechanism, endpoint validity, and survival gains met European scientific standards under the EU Clinical Trials Regulation (CTR) & CTIS framework.
Aumseqa represents a similar milestone, establishing that high-quality trial data audited under ICH GCP (Good Clinical Practice) can support EU authorization regardless of trial origin. Meanwhile, Baxfendy addresses the long-standing challenge of excess aldosterone signaling in uncontrolled arterial hypertension.
Under EU-M4All (governed by Article 58 of Regulation (EC) No 726/2004), the EMA evaluates medicines intended exclusively for low- and middle-income nations in partnership with the World Health Organization. In this review, regulators from the Kenya Pharmacy and Poisons Board, South African Health Products Regulatory Authority, and Zambia Medicines Regulatory Authority participated directly as co-evaluators, streamlining future domestic licensing. Sponsors tracking European trial transitions from the legacy EudraCT Database to CTIS frequently navigate these international pathways alongside early-access mechanisms, as reviewed in Expanded Access vs. Compassionate Use.
Stakeholder reactions and regulatory perspectives
The positive opinions drew strong responses across oncology, cardiology, and global health. The Population Council highlighted that the three-month dapivirine ring reduces annual product costs by nearly 60 percent compared to the monthly ring. The African Women’s HIV Prevention Accountability Board praised the quarterly schedule for reducing clinic travel and privacy challenges that affect PrEP adherence.
Population Council will transfer commercial licensing to Kiara Health in South Africa to establish regional manufacturing and spearhead distribution. In cardiovascular medicine, AstraZeneca emphasized that selective aldosterone synthase inhibition addresses a critical unmet need in uncontrolled hypertension. Oncology clinicians noted that sintilimab’s EU approval validates international oncology data while introducing needed price competition among checkpoint inhibitors.
What it means for researchers, universities and research offices
The CHMP decisions provide practical implications for trial sponsors, academic medical centers, and university research offices:
- Trial Diversity and Multi-Regional Strategy: The divergence between EMA and FDA on sintilimab shows that European authorities assess data integrity, disease biology, and trial conduct without disqualifying single-region studies. Sponsors can utilize robust foreign trial packages for EU submissions while planning supplementary cohorts for US applications.
- Investigator-Initiated Trial Comparators: Approvals of biosimilar insulins and generic ruxolitinib substantially reduce drug acquisition costs for university hospitals and academic consortia conducting clinical trials in oncology, immunology, and metabolic disease.
- Collaborative Global Health Submissions: Academic developers working on neglected or high-burden diseases should leverage the EU-M4All framework early. Joint reviews involving WHO and African regulators avoid redundant national filings and harmonize clinical endpoints.
- Transition from Compassionate Protocols: Research institutions providing investigational therapies under early access must prepare for standard commercial transition as European Commission decisions take effect, updating institutional pharmacy budgets and clinical supply chains.
What happens next
The CHMP recommendations now advance to the European Commission, which typically issues legally binding marketing authorizations within 67 days, placing final EU approvals in January 2027. These authorizations apply across all 27 EU member states, Iceland, Liechtenstein, and Norway.
Following Commission approval, national health technology assessment (HTA) bodies will conduct clinical and economic assessments under member state pricing rules to determine reimbursement. For the three-month dapivirine ring, Population Council and Kiara Health will submit registration dossiers to national regulatory authorities across sub-Saharan Africa, using WHO prequalification and reliance pathways to accelerate access through 2027.
Sources
- European Medicines Agency: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026, checked 2026-11-20
- Syenza News: CHMP November 2026 Recommends Seven New Medicines for Approval, checked 2026-11-20
- Population Council: Council’s 3-Month HIV Prevention Product Receives Positive Scientific Opinion from EMA, checked 2026-11-20
- Contagion Live: EMA Backs 3-Month Dapivirine Ring for HIV Prevention in Women, checked 2026-11-20
- OncLive: Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC, checked 2026-11-20







